Argenx Unnatural Products acquisition pays 550 million dollars upfront for macrocyclic peptides
Argenx will pay $550 million upfront and up to $595 million in milestones for Santa Cruz peptide developer Unnatural Products. No programs, targets or clinical candidates were disclosed, and closing is expected by the end of 2026.
SANTA CRUZ, CA
$550MUpfront cash Argenx will pay, with up to $595 million more tied to development and regulatory milestones
- What's newArgenx agreed on November 9, 2026 to acquire Santa Cruz macrocyclic peptide developer Unnatural Products for $550 million upfront and up to $595 million in milestones, a potential total of about $1.15 billion.
- Why it mattersThe deal moves an antibody focused immunology company into oral and long acting peptide discovery, following FDA approvals of oral peptides such as Icotyde and Lipfendra in 2026.
- What's nextArgenx expects the deal to close by the end of 2026. No programs, targets or clinical candidates have been disclosed, so the next signal would be a named program or a first human study.
